Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 7/2009

Open Access 01-07-2009 | Article

Associations between autoantibodies against apolipoprotein B-100 peptides and vascular complications in patients with type 2 diabetes

Authors: G. N. Fredrikson, D. V. Anand, D. Hopkins, R. Corder, R. Alm, E. Bengtsson, P. K. Shah, A. Lahiri, J. Nilsson

Published in: Diabetologia | Issue 7/2009

Login to get access

Abstract

Aims/hypothesis

Oxidation of LDL in the arterial extracellular matrix is a key event in the development of atherosclerosis and autoantibodies against oxidised LDL antigens reflect disease severity and the risk of developing acute cardiovascular events. Since type 2 diabetes is associated with increased oxidative stress, we tested the hypothesis that autoantibodies against oxidised LDL antigens are biomarkers for vascular complications in diabetes.

Methods

We studied 497 patients with type 2 diabetes without clinical signs of coronary heart disease. Oxidised LDL autoantibodies were determined by ELISA detecting IgG and IgM specific for native and malondialdehyde (MDA)-modified apolipoprotein B-100 peptides p45 and p210. The severity of coronary disease was assessed as the coronary artery calcium score.

Results

Patients affected by retinopathy had significantly higher levels of IgG against MDA-p45 and MDA-p210. In contrast, high levels of autoantibodies against the corresponding native peptides were associated with less coronary calcification and a lower risk of progression of coronary disease.

Conclusions/interpretation

Our observations suggest that LDL oxidation is involved in the pathogenesis of diabetic retinopathy and that autoantibodies against apolipoprotein B peptides may act as biomarkers for both micro- and macrovascular complications in diabetes.
Literature
1.
Binder CJ, Chang MK, Shaw PX et al (2002) Innate and acquired immunity in atherogenesis. Nat Med 8:1218–1226PubMedCrossRef
2.
Hansson GK, Libby P (2006) The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6:508–519PubMedCrossRef
3.
Bjorkbacka H, Kunjathoor VV, Moore KJ et al (2004) Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 10:416–421PubMedCrossRef
4.
Michelsen KS, Wong MH, Shah PK et al (2004) Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U S A 101:10679–10684PubMedCrossRef
5.
Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C (1997) IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest 99:2752–2761PubMedCrossRef
6.
Lee TS, Yen HC, Pan CC, Chau LY (1999) The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 19:734–742PubMed
7.
Tupin E, Nicoletti A, Elhage R et al (2004) CD1d-dependent activation of NKT cells aggravates atherosclerosis. J Exp Med 199:417–422PubMedCrossRef
8.
Zhou X, Robertson AK, Rudling M, Parini P, Hansson GK (2005) Lesion development and response to immunization reveal a complex role for CD4 in atherosclerosis. Circ Res 96:427–434PubMedCrossRef
9.
10.
Palinski W, Witztum JL (2000) Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J Intern Med 247:371–380PubMedCrossRef
11.
Hulthe J (2004) Antibodies to oxidized LDL in atherosclerosis development—clinical and animal studies. Clin Chim Acta 348:1–8PubMedCrossRef
12.
Palinski W, Miller E, Witztum JL (1995) Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci U S A 92:821–825PubMedCrossRef
13.
Ameli S, Hultgardh-Nilsson A, Regnstrom J et al (1996) Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 16:1074–1079PubMed
14.
Nilsson J, Calara F, Regnstrom J et al (1997) Immunization with homologous oxidized low density lipoprotein reduces neointimal formation after balloon injury in hypercholesterolemic rabbits. J Am Coll Cardiol 30:1886–1891PubMedCrossRef
15.
George J, Afek A, Gilburd B et al (1998) Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 138:147–152PubMedCrossRef
16.
Zhou X, Caligiuri G, Hamsten A, Lefvert AK, Hansson GK (2001) LDL immunization induces T cell-dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol 21:108–114PubMedCrossRef
17.
Nilsson J, Hansson GK (2008) Autoimmunity in atherosclerosis: a protective response losing control? J Intern Med 263:464–478PubMedCrossRef
18.
Nilsson J, Hansson GK, Shah PK (2005) Immunomodulation of atherosclerosis: implications for vaccine development. Arterioscler Thromb Vasc Biol 25:18–28PubMedCrossRef
19.
Fredrikson GN, Hedblad B, Berglund G et al (2003) Identification of immune responses against aldehyde-modified peptide sequences in apo B-100 associated with cardiovascular disease. Arterioscler Thromb Vasc Biol 23:872–878PubMedCrossRef
20.
Fredrikson GN, Soderberg I, Lindholm M et al (2003) Inhibition of atherosclerosis in ApoE-null mice by immunization with ApoB-100 peptide sequences. Arterioscler Thromb Vasc Biol 23:879–884PubMedCrossRef
21.
Fredrikson GN, Andersson L, Soderberg I et al (2005) Atheroprotective immunization with MDA-modified apo B-100 peptide sequences is associated with activation of Th2 specific antibody expression. Autoimmunity 38:171–179PubMedCrossRef
22.
Fredrikson GN, Schiopu A, Berglund G, Alm R, Shah PK, Nilsson J (2007) Autoantibody against the amino acid sequence 661–680 in apo B-100 is associated with decreased carotid stenosis and cardiovascular events. Atherosclerosis 194:e188–e192PubMedCrossRef
23.
Sjogren P, Fredrikson GN, Samnegard A et al (2008) High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction. Eur Heart J 29:2218–2226PubMedCrossRef
24.
Fredrikson GN, Hedblad B, Berglund G et al (2007) Association between IgM against an aldehyde-modified peptide in apolipoprotein B-100 and progression of carotid disease. Stroke 38:1495–1500PubMedCrossRef
25.
Nilsson J, Bengtsson E, Fredrikson GN, Bjorkbacka H (2008) Inflammation and immunity in diabetic vascular complications. Curr Opin Lipidol 19:519–524PubMedCrossRef
26.
Anand DV, Lim E, Hopkins D et al (2006) Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy. Eur Heart J 27:713–721PubMedCrossRef
27.
Harding S, Greenwood R, Aldington S et al (2003) Grading and disease management in national screening for diabetic retinopathy in England and Wales. Diabet Med 20:965–971PubMedCrossRef
28.
Anand DV, Lahiri A, Lim E, Hopkins D, Corder R (2006) The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 47:1850–1857PubMedCrossRef
29.
Shaw LJ, Raggi P, Schisterman E, Berman DS, Callister TQ (2003) Prognostic value of cardiac risk factors and coronary artery calcium screening for all-cause mortality. Radiology 228:826–833PubMedCrossRef
30.
Anand DV, Lim E, Darko D et al (2007) Determinants of progression of coronary artery calcification in type 2 diabetes role of glycemic control and inflammatory/vascular calcification markers. J Am Coll Cardiol 50:2218–2225PubMedCrossRef
31.
Berliner J, Leitinger N, Watson A, Huber J, Fogelman A, Navab M (1997) Oxidized lipids in atherogenesis: formation, destruction and action. Thromb Haemost 78:195–199PubMed
32.
Leitinger N (2003) Oxidized phospholipids as modulators of inflammation in atherosclerosis. Curr Opin Lipidol 14:421–430PubMedCrossRef
33.
Krauss RM (2004) Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 27:1496–1504PubMedCrossRef
34.
Chowdhury TA, Hopkins D, Dodson PM, Vafidis GC (2002) The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid lowering therapy? Eye 16:689–693PubMedCrossRef
35.
Chew EY, Klein ML, Ferris FL 3rd et al (1996) Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 114:1079–1084PubMed
36.
Hall NF, Gale CR, Syddall H, Phillips DI, Martyn CN (2001) Risk of macular degeneration in users of statins: cross sectional study. BMJ (Clin Res Ed) 323:375–376CrossRef
37.
Clark CM Jr, Lee DA (1995) Prevention and treatment of the complications of diabetes mellitus. N Engl J Med 332:1210–1217PubMedCrossRef
38.
Festa A, Kopp HP, Schernthaner G, Menzel EJ (1998) Autoantibodies to oxidised low density lipoproteins in IDDM are inversely related to metabolic control and microvascular complications. Diabetologia 41:350–356PubMedCrossRef
39.
Orchard TJ, Virella G, Forrest KY, Evans RW, Becker DJ, Lopes-Virella MF (1999) Antibodies to oxidized LDL predict coronary artery disease in type 1 diabetes: a nested case–control study from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 48:1454–1458PubMedCrossRef
40.
Lopes-Virella MF, Virella G, Orchard TJ et al (1999) Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin Immunol 90:165–172PubMedCrossRef
41.
Atchley DH, Lopes-Virella MF, Zheng D, Kenny D, Virella G (2002) Oxidized LDL-anti-oxidized LDL immune complexes and diabetic nephropathy. Diabetologia 45:1562–1571PubMedCrossRef
42.
Lehtimaki T, Lehtinen S, Solakivi T et al (1999) Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol 19:23–27PubMed
43.
Inoue T, Uchida T, Kamishirado H, Takayanagi K, Hayashi T, Morooka S (2001) Clinical significance of antibody against oxidized low density lipoprotein in patients with atherosclerotic coronary artery disease. J Am Coll Cardiol 37:775–779PubMedCrossRef
44.
Tornvall P, Waeg G, Nilsson J, Hamsten A, Regnstrom J (2003) Autoantibodies against modified low-density lipoproteins in coronary artery disease. Atherosclerosis 167:347–353PubMedCrossRef
45.
Boullier A, Hamon M, Walters-Laporte E et al (1995) Detection of autoantibodies against oxidized low-density lipoproteins and of IgG-bound low density lipoproteins in patients with coronary artery disease. Clin Chim Acta 238:1–10PubMedCrossRef
46.
Rossi GP, Cesari M, de Toni R et al (2003) Antibodies to oxidized low-density lipoproteins and angiographically assessed coronary artery disease in white patients. Circulation 108:2467–2472PubMedCrossRef
47.
Karvonen J, Paivansalo M, Kesaniemi YA, Horkko S (2003) Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation 108:2107–2112PubMedCrossRef
Metadata
Title
Associations between autoantibodies against apolipoprotein B-100 peptides and vascular complications in patients with type 2 diabetes
Authors
G. N. Fredrikson
D. V. Anand
D. Hopkins
R. Corder
R. Alm
E. Bengtsson
P. K. Shah
A. Lahiri
J. Nilsson
Publication date
01-07-2009
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 7/2009
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1377-9

Other articles of this Issue 7/2009

Diabetologia 7/2009 Go to the issue

Article

Assessing the effect of interaction between an FTO variant (rs9939609) and physical activity on obesity in 15,925 Swedish and 2,511 Finnish adults

Article

Relationship between glycated haemoglobin and microvascular complications: Is there a natural cut-off point for the diagnosis of diabetes?

Erratum

Accelerated atrophy of lower leg and foot muscles—a follow-up study of long-term diabetic polyneuropathy using magnetic resonance imaging (MRI)

Letter

Causal interpretation requires appropriate study design

Article

A genome-wide association scan for acute insulin response to glucose in Hispanic-Americans: the Insulin Resistance Atherosclerosis Family Study (IRAS FS)

OriginalPaper

Combined analysis of 19 common validated type 2 diabetes susceptibility gene variants shows moderate discriminative value and no evidence of gene–gene interaction
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits